CEO, Loncar Investments
Brad Loncar is an independent biotech investor and analyst, and has managed a biotech-focused family office since 2008. Through Loncar Investments LLC, he uses his research of biotech companies and technologies to develop thematic biotech investment indexes. The Loncar Cancer Immunotherapy Index was launched in March of 2015. It is the only of its kind and consists of 30 companies leading the way in the emerging field of cancer immunotherapy. Mr. Loncar previously worked at Franklin Templeton Investments and served in a Senior Advisor role at the U.S. Department of the Treasury. He is one of the most followed biotech commentators on social media and writes biotech commentary at www.LoncarBlog.com. He holds a BA in Finance from the University of Miami.